HC Wainwright & Co. Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $11
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Raghuram Selvaraju maintains a 'Buy' rating on BioXcel Therapeutics but lowers the price target from $60 to $11.
August 18, 2023 | 10:27 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
BioXcel Therapeutics' price target has been lowered from $60 to $11 by HC Wainwright & Co., though the 'Buy' rating is maintained.
The significant reduction in price target by HC Wainwright & Co. could negatively impact investor sentiment and potentially lead to a short-term decrease in BioXcel Therapeutics' stock price. However, the maintained 'Buy' rating indicates that the analyst still sees potential in the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100